CELLULAR INTERACTIONS RESPONSIBLE FOR DEVELOPMENT, MAINTENANCE, AND STRENGTH OF THE SKELETON
With
Prof Natalie A Sims, PhD.
Deputy Director, St. Vincent’s Institute,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | May 2025
Professor Sims directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute of Medical Research and is a Professorial Fellow at The University of Melbourne and Australian Catholic University.
She leads a team who studies the cellular interactions responsible for development, maintenance, and strength of the skeleton. She completed her PhD at the University of Adelaide, followed by postdoctoral work at the Garvan Institute in Sydney then at Yale School of Medicine, in New Haven, Connecticut, where she studied the role of the estrogen receptor in regulating bone structure.
She returned to Australia in 2001 to set up a laboratory at St. Vincent’s Hospital and SVI. Her laboratory studies the cellular interactions responsible for development, maintenance, and strength of the skeleton, including the IL-6 family of cytokines, using genetically altered mouse models, in vitro system and human specimens. She has published more than 140 peer reviewed original research articles, 48 peer reviewed review articles and commentaries, and 20 published chapters; H index of 64 (Scopus); more than 13,500 career citations.
Her work has been recognised by awards from her colleagues internationally, including the International Bone and Mineral Society Herbert A Fleisch Award (2013) and the American Society of Bone and Mineral Research (ASBMR) Fuller Albright Award (2010) and Paula Stern Award (2020).
She is a Deputy Editor of the Journal of Bone and Mineral Research and serves on the Editorial Board of the Journal of Biological Chemistry. She has served as President of the Australia and New Zealand Bone and Mineral Society and is currently Executive Secretary of the International Federation of Musculoskeletal Research Societies.
Source: Supplied
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
-
Identification, characterisation and role of leader cells in ovarian cancer progression
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
-
New treatments for patients with mental illness
Associate Professor Bernadette Fitzgibbon is a neuroscientist with several decades of experience in researching, developing, and translating novel therapies for mental health and chronic pain conditions. This includes the application and optimisation of brain stimulation and psychedelic therapies, overseeing large multi-site intervention trials, both within Australia and abroad. Through her work, she has developed meaningful collaborations with consumers, volunteers, policy makers, and services providers, ensuring that the outcomes of her work contribute towards real-world clinical impact.
